Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Receivables (2019 - 2025)

Historic Receivables for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $100.7 million.

  • Harmony Biosciences Holdings' Receivables rose 2349.51% to $100.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.7 million, marking a year-over-year increase of 2349.51%. This contributed to the annual value of $83.0 million for FY2024, which is 1199.49% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Receivables of $100.7 million as of Q3 2025, which was up 2349.51% from $93.0 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Receivables' 5-year high stood at $106.0 million during Q1 2025, with a 5-year trough of $23.6 million in Q1 2021.
  • In the last 5 years, Harmony Biosciences Holdings' Receivables had a median value of $63.8 million in 2023 and averaged $63.4 million.
  • Its Receivables has fluctuated over the past 5 years, first soared by 10339.34% in 2021, then surged by 1181.38% in 2025.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Receivables stood at $34.8 million in 2021, then soared by 57.1% to $54.7 million in 2022, then surged by 35.44% to $74.1 million in 2023, then increased by 11.99% to $83.0 million in 2024, then grew by 21.22% to $100.7 million in 2025.
  • Its Receivables was $100.7 million in Q3 2025, compared to $93.0 million in Q2 2025 and $106.0 million in Q1 2025.